Quininib, a CysLT1 antagonist, is an anti-inflammatory and anti-angiogenic [58, 63] molecule with anti-cancer activity in human ex vivo colorectal cancer patient tumor explants and colorectal cancer xenograft models [64]. This evidence concerns the gene CYSLTR1 and neoplasm.